Neoadjuvant therapy with anlotinib in a 5-year-old child with advanced papillary thyroid carcinoma: a case report - Takeaways - MDSpire

Neoadjuvant therapy with anlotinib in a 5-year-old child with advanced papillary thyroid carcinoma: a case report

  • By

  • Yuan Gong

  • Hongjiang Ma

  • Mingyang Lu

  • Qiuyu Meng

  • Bin Liu

  • Tingting Yang

  • Haifeng Ma

  • Yanjun Su

  • Ruochuan Cheng

  • May 13, 2026

  • 0 min

Share

  • 1

    Anlotinib, a multi-target tyrosine kinase inhibitor, was used as neoadjuvant therapy for a 5-year-old with advanced papillary thyroid carcinoma.

  • 2

    The patient presented with locally advanced thyroid cancer, including widespread lymph node and pulmonary metastases, making the tumor initially unresectable.

  • 3

    After three cycles of anlotinib treatment, the tumor showed sufficient regression, allowing for successful surgical resection.

  • 4

    No significant adverse reactions were observed during anlotinib therapy, with permanent hypoparathyroidism being the only complication post-surgery.

  • 5

    This case highlights the potential of anlotinib as a neoadjuvant treatment option for pediatric patients with locally advanced thyroid cancer.

Original Source(s)

Neoadjuvant therapy with anlotinib in a 5-year-old child with advanced papillary thyroid carcinoma: a case report

  • by Yuan Gong, Hongjiang Ma, Mingyang Lu, Qiuyu Meng, Bin Liu, Tingting Yang, Haifeng Ma, Yanjun Su, Ruochuan Cheng

  • May 13, 2026

Related Content

Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer

The role of NAD+ metabolic reprogramming in colorectal cancer chemoresistance: mechanistic insights, clinical translation challenges and opportunities

Case Report: Synovial sarcoma with diffuse myxoid stroma and complete absence of epithelial differentiation in the extremity